Form 8-K

8-K — Akari Therapeutics Plc

Accession: 0001493152-26-031972

Filed: 2026-07-02

Period: 2026-06-30

CIK: 0001541157

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001541157

2026-06-30

0001541157

AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember

2026-06-30

0001541157

AKTX:OrdinarySharesParValue0.000000005PerShareMember

2026-06-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 30, 2026

Akari

Therapeutics, Plc

(Exact

Name of Registrant as Specified in Charter)

England

and Wales

001-36288

98-1034922

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

401

East Jackson Street, Suite 3300

Tampa,

FL 33602

(Address,

including zip code, of Principal Executive Offices)

Registrant’s

telephone number, including area code: (929) 274-7510

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class:

Trading

Symbol(s)

Name

of each

exchange

on which registered

American

Depositary Shares, each representing 80,000 Ordinary Shares

AKTX

The

Nasdaq Capital Market

Ordinary

Shares, par value $0.000000005 per share*

*Trading,

but only in connection with the American Depositary Shares.

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.07. Submission of Matters to a Vote of Security Holders.

June 30, 2026, Akari Therapeutics, Plc (the “Company”) held its Annual General Meeting. Proxies were solicited

pursuant to the Company’s Proxy Statement, with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange

Act of 1934, as amended. The number of ordinary shares entitled to vote at the Annual General Meeting was 140,032,769,533. The number

of ordinary shares present or represented by valid proxy at the Annual General Meeting established a quorum for the Annual General Meeting.

The Annual General Meeting duly proceeded in accordance with the provisions of the articles of association of the Company.

The

voting results below are final and reported in ordinary shares.

Ordinary

Resolution

For

Against

Abstain

receive the report of the Board of Directors and the accounts for the year ended December 31, 2025, together with the report of the

statutory auditor and the strategic report.

59,475,894,977

160,000

152,962,489

approve, on an advisory-basis, the Board of Directors’ Remuneration Report (excluding the Board of Directors’ Remuneration

Policy), as set out in the Company’s annual report and accounts for the financial year ended December 31, 2025.

41,140,049,749

944,080,000

17,544,887,717

approve, the Directors’ Remuneration Policy, as set out in the Company’s annual report and accounts for the financial

year ended December 31, 2025.

38,441,889,749

3,648,160,000

17,538,967,717

re-elect Hoyoung Huh as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Company’s articles of

association (the “Articles”).

31,783,014,977

5,492,720,000

22,353,282,489

re-elect Robert Bazemore as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.

41,548,134,977

553,840,000

17,527,042,489

re-elect James Neal as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.

13,069,414,977

29,032,560,000

17,527,042,489

re-elect Sandip I. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.

41,560,694,977

541,280,000

17,527,042,489

re-elect Samir R. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.

41,560,694,977

529,680,000

17,538,642,489

re-elect Abizer Gaslightwala as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles.

42,095,414,977

480,000

17,533,122,489

ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31,

2026.

59,487,814,977

160,000

141,042,489

re-appoint HaysMac LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which

accounts are laid before Akari shareholders.

59,457,974,977

29,840,000

141,202,489

authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.

58,806,054,977

666,320,000

156,642,489

approve, on a non-binding, advisory basis, the compensation of our named executive officers (“NEOs”) as disclosed in

the Proxy Statement.

38,483,569,749

3,600,320,000

17,545,127,717

approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of ordinary shares, pursuant to the Company’s ELOC Purchase

Agreement.

37,958,854,977

4,141,360,000

17,528,802,489

approve, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Series H Warrants, Series I Warrants and

Series J Warrants to purchase up to an aggregate of 4,411,764 American Depositary Shares pursuant to a securities purchase agreement

dated May 20, 2026 and the issuance of the ADSs and ordinary shares underlying such warrants, and an aggregate of 117,647 placement

agent ADSs pursuant to a placement agent agreement dated May 20, 2026.

37,806,614,977

4,299,760,000

17,522,642,489

approve, in accordance with Nasdaq Listing Rule 5635(b), the potential issuance of shares in a private placement offering, which

would result in a “change of control” of the Company.

38,003,814,977

4,102,480,000

17,522,722,489

That,

in accordance with section 551 of the U.K. Companies Act 2006, our directors or any duly authorized committee of the directors be

generally and unconditionally authorized to allot shares in Akari and to grant rights to subscribe for or to convert any security

into shares in Akari up to an aggregate nominal amount of USD 20,000 for a period expiring (unless otherwise renewed, varied or revoked

by Akari at a general meeting) on June 30, 2031 (the “General Allotment Proposal”), save that Akari may, before such

expiry, make offers or agreements which would or might require such shares to be allotted or such rights to be granted after such

expiry and the directors may allot such shares or grant such rights in pursuance of such offers or agreements notwithstanding that

the authority conferred by this resolution has expired; and this resolution revokes and replaces all unexercised authorities previously

granted to the directors to allot shares or grant rights to subscribe for or convert any security into shares, but without prejudice

to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.

53,833,094,977

5,690,480,000

105,442,489

Special

Resolution

For

Against

Abstain

That,

conditional the General Allotment Proposal being duly passed, in accordance with section

570 of the U.K. Companies Act 2006, the directors of Akari (or any duly authorized committee

of the directors of Akari) be generally empowered to allot equity securities (as defined

in section 560 of the U.K. Companies Act 2006) for cash pursuant to the authorization conferred

on them by the General Allotment Proposal as if section 561 of the U.K. Companies Act 2006

and any pre-emption provisions in the Articles (or howsoever otherwise arising) did not apply

to the allotment for a period expiring (unless previously renewed, varied or revoked by Akari

prior to or on that date) five years after the date on which this resolution is passed save

that Akari may, before such expiry, make an offer or agreement which would or might require

shares to be allotted after such expiry and the directors may allot shares in pursuance of

any such offer or agreement notwithstanding that the power conferred by this resolution has

expired.

53,853,889,749

5,667,120,000

108,007,717

At the Annual General Meeting,

James Neal was not re-elected to the Board of Directors, having failed to receive the requisite shareholder approval. Accordingly, Mr.

Neal’s service as a director ended upon the conclusion of the Annual General Meeting. Mr. Neal served as a member of the Audit

Committee and Chair of the Compensation Committee of the Board of Directors immediately prior to the Annual General Meeting. Accordingly,

subsequent to the Annual General Meeting, the Board of Directors appointed Dr. Ray Prudo to serve as a member of the Audit Committee,

effective immediately, and Robert Bazemore, a current member of the Compensation Committee, was appointed Chair.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

104

The

cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Akari

Therapeutics, Plc

Date:

July 2, 2026

By:

/s/

Kameel Farag

Kameel

Farag

Interim

Chief Financial Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 30, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 30, 2026

Entity File Number

001-36288

Entity Registrant Name

Akari

Therapeutics, Plc

Entity Central Index Key

0001541157

Entity Tax Identification Number

98-1034922

Entity Incorporation, State or Country Code

Entity Address, Address Line One

401

East Jackson Street

Entity Address, Address Line Two

Suite 3300

Entity Address, City or Town

Tampa

Entity Address, State or Province

Entity Address, Postal Zip Code

33602

City Area Code

(929)

Local Phone Number

274-7510

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

American Depositary Shares, each representing 80,000 Ordinary Shares

Title of 12(b) Security

American

Depositary Shares, each representing 80,000 Ordinary Shares

Trading Symbol

AKTX

Security Exchange Name

NASDAQ

Ordinary Shares, par value $0.000000005 per share*

Title of 12(b) Security

Ordinary

Shares, par value $0.000000005 per share*

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=AKTX_AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=AKTX_OrdinarySharesParValue0.000000005PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: